Various inhibitors of CDK1, including flavopiridol, BMI-1026, olomoucine, staurosporine, and RO-3306 have been developed, and some have entered phase I and II clinical trials for the treatment of a variety of solid tumors and hematologic malignancies (Wang et al., 2011). The gene discussed is CDK1; the disease is hematologic disorder.